US 11,692,213 B2
Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using CRISPR/Cas system proteins
Meredith L. Carpenter, San Mateo, CA (US); Carlos D. Bustamante, Emerald Hills, CA (US); and Stephane B. Gourguechon, San Mateo, CA (US)
Assigned to ARC BIO, LLC, Scotts Valley, CA (US)
Filed by Arc Bio, LLC, Cambridge, MA (US)
Filed on Aug. 3, 2020, as Appl. No. 16/983,388.
Application 16/983,388 is a continuation of application No. 15/537,962, granted, now 10,774,365, previously published as PCT/US2015/066949, filed on Dec. 19, 2015.
Claims priority of provisional application 62/198,097, filed on Jul. 28, 2015.
Claims priority of provisional application 62/094,980, filed on Dec. 20, 2014.
Prior Publication US 2021/0189459 A1, Jun. 24, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/00 (2006.01); C12Q 1/6806 (2018.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12Q 1/6874 (2018.01)
CPC C12Q 1/6806 (2013.01) [C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12Q 1/6874 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)] 14 Claims
 
1. A composition comprising a mixture of DNA targeted sequences for depletion and DNA sequences of interest, wherein the DNA targeted sequences for depletion and the DNA sequences of interest are adapter-ligated, wherein the adapters are ligated to both the 5′ and 3′ ends of both the target sequences for depletion and the sequences of interest, and wherein the DNA targeted sequences for depletion are complexed to a gRNA-CRISPR/Cas system protein complex and wherein the DNA sequences of interest are in the range of about 0.1% to about 50% of the DNA in the composition, wherein the CRISPR/Cas system protein is Cas9, Cpf1, Cas3, Cas8a-c, Cas10, Csel, Csyl, Csn2, Cas4, Csm2, or CmS.